摘要
目的 探讨布拉酵母菌联合三联疗法对幽门螺杆菌（Hp）根除率及根除治疗中不良反应发生率的影响.方法 选择120例接受胃镜检查并明确有Hp感染的患者,按随机数字表法分为标准三联组和布拉酵母菌组,每组60例,两组均给予标准三联疗法根除Hp治疗,疗程7d,布拉酵母菌组同时每天服用500 mg布拉酵母菌.治疗期间观察两组不良反应发生情况.治疗结束4周后行13C或14C尿素呼气试验以评估Hp根除情况.结果 布拉酵母菌组Hp根除率高于标准三联组[80.00％（48/60）比73.33％（44/60）],但两组比较差异无统计学意义（P=0.542）.两组在治疗期间共记录到上腹部不适、恶心、腹泻、味觉紊乱、转氨酶升高5种不良反应,其中布拉酵母菌组上腹部不适和腹泻发生率显著低于标准三联组[13.33％ （8/60）比43.33％（26/60）,3.33％（2/60）比26.67％（16/60）],差异有统计学意义（P＜0.05）.结论 布拉酵母菌联合标准三联疗法不能明显提高Hp根除率,但可以减少Hp根除过程中不良反应的发生率,提高Hp根除治疗的依从性.
Objective To evaluate the potential activity ofSaccharomyces boulardii as an adjuvant to triple therapy for Helicobacter pylori infection,so as to forecast the probable effectiveness of Saccharomyces boulardii in the eradication of Helicobacter pylori and the adverse reaction.Methods A total of 120 patients who received gastroscopy and tested positive for Helicobacter pylori infection were divided into standard triple therapy group and Saccharomyces boulardii group with 60 cases each by random digits table method.Patients were randomized to receive one week standard triple therapy,supplemented with Saccharomyces boulardii in Saccharomyces boulardii group.Saccharomyces boulardii was taken 500 mg per day for one week.All adverse reactions were recorded during the treatment period.13C or 14C urea breath test was performed at four weeks after the end of triple therapy to evaluate the situation of Helicobacter pylori eradication.Results Helicobacter pylori eradication rate in Saccharomyces boulardii group was higher than that in standard triple therapy group [80.00% （48/60） vs.73.33% （44/60）],but there was no significant difference （P =0.542）.Five adverse reactions including epigastric discomfort,nausea,diarrhea,taste disorder and liver injury were recorded during the treatment period.The incidence of adverse reactions such as epigastric discomfort and diarrhea in Saccharomyces boulardii group was significantly lower than that in standard triple therapy group [13.33% （8/60）vs.43.33%（26/60）,3.33%（2/60） vs.26.67%（16/60）],and there was significant difference （P 〈 0.05）.Conclusion Saccharomyces boulardii as an adjuvant to triple therapy can not improve Helicobacter pylori eradication rate,but can decrease the incidence of adverse reactions during the treatment period and improve the complicance of Helicobacter pylori eradication treatment.
出处
《中国医师进修杂志》
2013年第34期10-12,共3页
Chinese Journal of Postgraduates of Medicine
基金
沈阳市科学技术计划（F13-318-1-42）
关键词
螺杆菌
幽门
益生菌
布拉酵母菌
根除率
Helicobacter pylori
Probiotics
Saccharomyces boulardii
Eradication rate
